South Carolina Secures $73 Million from Purdue-Sackler Opioid Settlement

Nearly a decade after first suing Purdue Pharma for its role in fueling the opioid crisis, South Carolina is set to receive approximately $73 million from the landmark $7.4 billion settlement with the OxyContin manufacturer and its owners, the Sackler family. The agreement, which became legally effective May 1, 2026, represents a significant milestone in the state's ongoing efforts to hold pharmaceutical companies accountable for the epidemic that has claimed thousands of lives across the Palmetto State.

Attorney General Alan Wilson, whose office filed suit against Purdue in 2017, announced that South Carolina will receive approximately $72.8 million over the next 15 years. The funds are designated specifically for addiction recovery and prevention programs, targeting the families and communities most affected by what Wilson's office described as "the largest drug crisis in the country's history."

"We were one of the first states that sued Purdue back in 2017 to hold this company accountable for the opioid epidemic that has killed thousands of South Carolinians," Wilson said in a statement. "The bankruptcy and appeals process has delayed resolution for years, but with this step, we're finally nearing the finish line."

A Decade of Legal Pursuit

The settlement culminates years of complex litigation that began when attorneys general from across the country launched a multistate investigation of Purdue in 2016. South Carolina was among the early adopters, filing its lawsuit the following year and accusing the company of "unfairly and deceptively" marketing opioids while downplaying their addictive potential and overstating their benefits compared to alternative pain management approaches.

The legal battle intensified after Purdue filed for bankruptcy in September 2019, a move that initially threatened to shield the company and the Sackler family from full financial responsibility. The path to resolution required navigating bankruptcy proceedings, appeals, and a critical Supreme Court decision in June 2024 that invalidated provisions in an earlier settlement agreement, ultimately forcing the Sacklers to contribute more to the final deal.

The current settlement, signed onto by 55 attorneys general representing all eligible U.S. states and territories, permanently bars the Sackler family from selling opioids in the United States. It also mandates that Purdue's manufacturing operations transfer to Knoa Pharma LLC, a new entity overseen by a board with no connection to the original company. Knoa will be prohibited from marketing opioids and will operate under independent monitoring to ensure the safest possible distribution practices.

Distribution Timeline and Transparency Requirements

The financial structure of the settlement front-loads payments to maximize immediate impact. The Sacklers are paying more than $1.5 billion immediately, followed by approximately $500 million in May 2027, another $500 million in May 2028, and $400 million in May 2029. Purdue itself is contributing approximately $900 million today.

Beyond the financial provisions, the settlement requires Purdue and the Sacklers to make public more than 30 million documents related to their opioid business operations. This disclosure could provide researchers, policymakers, and the public with unprecedented insight into the internal decision-making that contributed to the crisis.

South Carolina's Broader Recovery Effort

The Purdue-Sackler settlement represents just one component of South Carolina's comprehensive legal strategy against opioid industry players. Attorney General Wilson's office has pursued litigation against multiple other companies, securing additional funds that substantially expand the state's resources for addressing the crisis.

In 2019, Wilson sued the three major opioid distributors—Cardinal, McKesson, and AmerisourceBergen (now Cencora). The state has also reached settlements with manufacturers including Janssen, Allergan, and Teva, as well as major pharmacy chains Walmart, Walgreens, CVS, and Kroger. Recovery from manufacturers Endo and Mallinckrodt came through bankruptcy claims, and additional settlements were announced last summer with Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus.

When combined, these legal actions have secured more than $256 million in funds for opioid abatement programs throughout South Carolina. With the additional $500 million expected over the next 15 years from the Purdue-Sackler settlement and other agreements, Wilson projects that total state recovery will exceed three-quarters of a billion dollars.

The Challenge of Effective Deployment

While the influx of settlement funds represents a historic opportunity, experts caution that the money's impact will depend heavily on how it is allocated and spent. South Carolina, like other states receiving opioid settlement dollars, faces the challenge of deploying these resources effectively to reduce addiction and support recovery.

The settlement agreements generally require that funds be used for opioid abatement programs, including addiction treatment, prevention, and recovery services. However, the specific allocation decisions often fall to state and local officials, creating variation in how different communities approach the crisis.

Chris Sharp, a senior fellow with the Cicero Institute, described the settlement funds as a "once-in-a-generation opportunity" in a guest column published earlier this year. Sharp emphasized the importance of ensuring that money is actually spent on opioid mitigation rather than diverted to cover budget shortfalls or unrelated projects. He also stressed the need to direct funds toward interventions that reduce addiction and restore lives, warning that without careful planning, the settlements could fail to deliver the change they promised.

Context of National Progress

The settlement takes effect during a period of cautious optimism in the fight against opioid-related deaths. National data shows overdose deaths have declined approximately 19 percent since peaking in August 2023, marking the longest sustained decrease in more than four decades. However, mortality rates remain well above pre-crisis levels, and public health officials warn that continued investment in treatment and prevention is essential to maintaining progress.

South Carolina's share of the Purdue-Sackler settlement will flow into communities over 15 years, providing a sustained funding stream rather than a one-time infusion. This structure aligns with the understanding that addressing the opioid crisis requires long-term commitment rather than short-term interventions. The challenge for state and local leaders will be translating these substantial financial resources into measurable improvements in public health outcomes.

As the first payments begin to arrive, attention will turn to how South Carolina deploys its recovery funds and whether the state can serve as a model for effective opioid abatement programming. With hundreds of millions of dollars now secured, the resources are in place—the question is whether they can be transformed into lasting change for communities devastated by the opioid epidemic.